Difference between revisions of "Talazoparib (Talzenna)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
PARP inhibitor | PARP inhibitor | ||
| + | |||
| + | *[https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8313 IUPHAR/BPS] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 14: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2019-06-20: Initial authorization as Talzenna. Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic [[breast cancer]]. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. ''(Based on EMBRACA)'' | *2019-06-20: Initial authorization as Talzenna. Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic [[breast cancer]]. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. ''(Based on EMBRACA)'' | ||
| + | *2023-11-09: CHMP recommends new marketing authorisation - Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant [[prostate cancer]] (mCRPC) in whom chemotherapy is not clinically indicated. | ||
==Also known as== | ==Also known as== | ||
| Line 21: | Line 24: | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | [[Category: | + | [[Category:PARP1 inhibitors]] |
| + | [[Category:PARP2 inhibitors]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
Revision as of 18:14, 19 November 2023
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 2018-10-16: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)
- 2023-06-20: Approved with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Based on TALAPRO-2)
History of changes in EMA indication
- 2019-06-20: Initial authorization as Talzenna. Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. (Based on EMBRACA)
- 2023-11-09: CHMP recommends new marketing authorisation - Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Also known as
- Code name: BMN-673
- Brand name: Talzenna